VIEWPOINTS


Viewpoints are a collection of news and opinion articles that capture key research developments and important issues in the field of oncology.


Bendamustine-triplet in Front-line Multiple Myeloma

Bendamustine-triplet in Front-line Multiple Myeloma

The combination of bendamustine, bortezomib, and dexamethasone was reported to be effective in achieving overall response rates in myeloma.

Weight Gain: A Risk Factor for Postmenopausal Breast Cancer

Weight Gain: A Risk Factor for Postmenopausal Breast Cancer

While women who lost more than 5 kg after age 18 were at a 23% reduced risk for breast cancer, those who gained more than 30 kg were at a 32% increased risk.

ASCO Advance of the Year: Immunotherapy 2.0

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.

Smoking Cessation After Diagnosis: A Consistent Survival Benefit

Smoking Cessation After Diagnosis: A Consistent Survival Benefit

Smoking cessation may improve survival regardless of the type of cancer diagnosed, due to a reduction in comorbidities.

Triple-negative Breast Cancer: New Strategies for Targeted Therapy

Triple-negative Breast Cancer: New Strategies for Targeted Therapy

Despite the success of targeted therapy in other cancers, targeted therapy has failed to improve outcomes in triple-negative breast cancer.

Selinexor for Relapsed/Refractory Multiple Myeloma

Selinexor for Relapsed/Refractory Multiple Myeloma

Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of heavily pre-treated patients with few options.

Prostate Cancer: Future of Research and Treatment

Prostate Cancer: Future of Research and Treatment

Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a positive sentinel node biopsy.

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Ponatinib: Black Box Warning and Drug Interactions

Ponatinib: Black Box Warning and Drug Interactions

If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.

Metastatic Prostate Cancer to the Gastrointestinal Tract

Metastatic Prostate Cancer to the Gastrointestinal Tract

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.

TKI Discontinuation and Chronic Myeloid Leukemia

TKI Discontinuation and Chronic Myeloid Leukemia

TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.

Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

Non-small Cell Lung Cancer: Cisplatin-etoposide vs Carboplatin-paclitaxel

Non-small Cell Lung Cancer: Cisplatin-etoposide vs Carboplatin-paclitaxel

A recent review suggests that cisplatin-etoposide and carboplatin-paclitaxel regimens are comparable in efficacy.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters